Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Cash per Share : $0.78 (As of Jun. 2021)

View and export this data going back to 2017. Start your Free Trial

What is Aerpio Pharmaceuticals Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Aerpio Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2021 was $0.78.

Aerpio Pharmaceuticals Cash per Share Historical Data

The historical data trend for Aerpio Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerpio Pharmaceuticals Cash per Share Chart

Aerpio Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash per Share

Get a 7-Day Free Trial

0.92

0.75

1.54

0.95

0.90

Aerpio Pharmaceuticals Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash per Share	Get a 7-Day Free Trial															1.11	1.00	0.90	0.82	0.78

Aerpio Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Aerpio Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2020 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	42.605	/	47.25
	=	0.90

Aerpio Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2021 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	36.816	/	47.48
	=	0.78

Aerpio Pharmaceuticals (NAS:ARPO) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Aerpio Pharmaceuticals Cash per Share Related Terms

Thank you for viewing the detailed overview of Aerpio Pharmaceuticals's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerpio Pharmaceuticals Inc (NAS:ARPO) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

9987 Carver Road, Cincinnati, OH, USA, 45242

Website

https://www.aerpio.com

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Pravin Dugel	director	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Steven Prelack	director	7 WHEELWRIGHT ROAD, MEDFIELD MA 02052
Regina Marek	officer: Vice President of Finance	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI OH 45242
Joseph H. Gardner	director, officer: President	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Kevin G. Peters	officer: See Remarks	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, C OH 45242
Muneer A Satter	director, 10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael W Rogers	officer: See Remarks	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Stephen J Hoffman	director, officer: Chief Executive Officer	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056